EPO Response to Anemia in Patients According to Time of Treatment
| Patient Group (no.) . | Median Duration of Treatment in Months Mean (range) . | Hb g/dL . | Regression Line Equation . | Coefficient of Correlation (r) . | P Value of Regression . | O/E log (EPO) Ratio Mean ± SD . | P Value Versus Controls . |
|---|---|---|---|---|---|---|---|
| Controls (23) | 9.1 ± 1.5 | log(EPO) = 3.48 − 0.20 Hb | −0.73 | <.001 | 1.00 ± 0.18 | — | |
| Aplastic anemia (10) | 7.4 ± 1.4 | log(EPO) = 5.05 − 0.33 Hb | −0.73 | <.01 | 1.33 ± 0.23 | <.001 | |
| Leukemic patients | |||||||
| At diagnosis (55) | 8.6 ± 2.2 | log(EPO) = 3.74 − 0.20 Hb | −0.63 | <.001 | 1.21 ± 0.33 | <.0001 | |
| During CT, early (29) | 2 (1-4) | 8.9 ± 1.6 | log(EPO) = 4.80 − 0.32 Hb | −0.78 | <.001 | 1.22 ± 0.29 | <.01 |
| During CT, late (24) | 5 (4-6) | 10.2 ± 1.9 | log(EPO) = 4.25 − 0.27 Hb | −0.74 | <.001 | 1.07 ± 0.37 | NS |
| Maintenance CT (15) | 9 (7-12) | 11.3 ± 1.0 | log(EPO) = 2.72 − 0.13 Hb | −0.33 | <.01 | 1.10 ± 0.30 | NS |
| Solid tumor patients | |||||||
| At diagnosis (56) | 10.7 ± 2.2 | log(EPO) = 3.32 − 0.21 Hb | −0.70 | <.001 | 0.90 ± 0.47 | NS | |
| During CT (31) | 4 (1-11) | 10.3 ± 1.6 | log(EPO) = 2.72 − 0.15 Hb | −0.47 | <.001 | 0.89 ± 0.37 | NS |
| CT with cisplatin (6) | 3 (1-6) | 10.6 ± 0.6 | log(EPO) = 2.28 − 0.13 Hb | −0.37 | <.01 | 0.70 ± 0.15 | <.05 |
| Patient Group (no.) . | Median Duration of Treatment in Months Mean (range) . | Hb g/dL . | Regression Line Equation . | Coefficient of Correlation (r) . | P Value of Regression . | O/E log (EPO) Ratio Mean ± SD . | P Value Versus Controls . |
|---|---|---|---|---|---|---|---|
| Controls (23) | 9.1 ± 1.5 | log(EPO) = 3.48 − 0.20 Hb | −0.73 | <.001 | 1.00 ± 0.18 | — | |
| Aplastic anemia (10) | 7.4 ± 1.4 | log(EPO) = 5.05 − 0.33 Hb | −0.73 | <.01 | 1.33 ± 0.23 | <.001 | |
| Leukemic patients | |||||||
| At diagnosis (55) | 8.6 ± 2.2 | log(EPO) = 3.74 − 0.20 Hb | −0.63 | <.001 | 1.21 ± 0.33 | <.0001 | |
| During CT, early (29) | 2 (1-4) | 8.9 ± 1.6 | log(EPO) = 4.80 − 0.32 Hb | −0.78 | <.001 | 1.22 ± 0.29 | <.01 |
| During CT, late (24) | 5 (4-6) | 10.2 ± 1.9 | log(EPO) = 4.25 − 0.27 Hb | −0.74 | <.001 | 1.07 ± 0.37 | NS |
| Maintenance CT (15) | 9 (7-12) | 11.3 ± 1.0 | log(EPO) = 2.72 − 0.13 Hb | −0.33 | <.01 | 1.10 ± 0.30 | NS |
| Solid tumor patients | |||||||
| At diagnosis (56) | 10.7 ± 2.2 | log(EPO) = 3.32 − 0.21 Hb | −0.70 | <.001 | 0.90 ± 0.47 | NS | |
| During CT (31) | 4 (1-11) | 10.3 ± 1.6 | log(EPO) = 2.72 − 0.15 Hb | −0.47 | <.001 | 0.89 ± 0.37 | NS |
| CT with cisplatin (6) | 3 (1-6) | 10.6 ± 0.6 | log(EPO) = 2.28 − 0.13 Hb | −0.37 | <.01 | 0.70 ± 0.15 | <.05 |
Abbreviations: CT, chemotherapy; NS, not significant.